These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 20961784)

  • 21. Incidence and risk factors of thrombocytopenia in patients receiving intermittent antiretroviral therapy: a substudy of the ANRS 106-window trial.
    Bouldouyre MA; Charreau I; Marchou B; Tangre P; Katlama C; Morlat P; Meiffredy V; Vittecoq D; Bierling P; Aboulker JP; Molina JM;
    J Acquir Immune Defic Syndr; 2009 Dec; 52(5):531-7. PubMed ID: 19855285
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neutropenia in human immunodeficiency virus infection: data from the women's interagency HIV study.
    Levine AM; Karim R; Mack W; Gravink DJ; Anastos K; Young M; Cohen M; Newman M; Augenbraun M; Gange S; Watts DH
    Arch Intern Med; 2006 Feb; 166(4):405-10. PubMed ID: 16505259
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immuno-Haematological Abnormalities of HIV-Infected Patients Before and After Initiation of Highly Active Antiretroviral Therapy in the Antiretroviral Therapy Clinics of Six Health Facilities at Dessie Town, Northeast Ethiopia.
    Tilahun M; Gedefie A; Ebrahim E; Seid A; Ali A; Shibabaw A; Belete MA; Fiseha M; Tesfaye M; Ebrahim H; Abera A
    J Blood Med; 2022; 13():243-253. PubMed ID: 35592587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence, severity, and duration of thrombocytopenia among HIV patients in the era of highly active antiretroviral therapy.
    Vannappagari V; Nkhoma ET; Atashili J; Laurent SS; Zhao H
    Platelets; 2011; 22(8):611-8. PubMed ID: 21612330
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in hematologic parameters and efficacy of thymidine analogue-based, highly active antiretroviral therapy: a meta-analysis of six prospective, randomized, comparative studies.
    Moyle G; Sawyer W; Law M; Amin J; Hill A
    Clin Ther; 2004 Jan; 26(1):92-7. PubMed ID: 14996521
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Response of severe HIV-associated thrombocytopenia to highly active antiretroviral therapy including protease inhibitors.
    Carbonara S; Fiorentino G; Serio G; Maggi P; Ingravallo G; Monno L; Bruno F; Coppola S; Pastore G; Angarano G
    J Infect; 2001 May; 42(4):251-6. PubMed ID: 11545567
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Magnitude and associated factors of cytopenias among antiretroviral therapy naïve Human Immunodeficiency Virus infected adults in Dessie, Northeast Ethiopia.
    Tamir Z; Seid A; Haileslassie H
    PLoS One; 2019; 14(2):e0211708. PubMed ID: 30759131
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impaired Hematological Status Increases the Risk of Mortality among HIV-Infected Adults Initiating Antiretroviral Therapy in Tanzania.
    Noor RA; Abioye AI; Hertzmark E; Darling AM; Aboud S; Mugusi FM; Sudfeld CR; Spiegelman D; Fawzi WW
    J Nutr; 2020 Sep; 150(9):2375-2382. PubMed ID: 32621487
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy.
    Giannini EG; Marenco S; Fazio V; Pieri G; Savarino V; Picciotto A
    Liver Int; 2012 Aug; 32(7):1113-9. PubMed ID: 22471814
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIV-1 transmitted drug resistance surveillance: shifting trends in study design and prevalence estimates.
    Rhee SY; Kassaye SG; Barrow G; Sundaramurthi JC; Jordan MR; Shafer RW
    J Int AIDS Soc; 2020 Sep; 23(9):e25611. PubMed ID: 32936523
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short-term clinical disease progression in HIV-infected patients receiving combination antiretroviral therapy: results from the TREAT Asia HIV observational database.
    Srasuebkul P; Lim PL; Lee MP; Kumarasamy N; Zhou J; Sirisanthana T; Li PC; Kamarulzaman A; Oka S; Phanuphak P; Vonthanak S; Merati TP; Chen YM; Sungkanuparph S; Tau G; Zhang F; Lee CK; Ditangco R; Pujari S; Choi JY; Smith J; Law MG
    Clin Infect Dis; 2009 Apr; 48(7):940-50. PubMed ID: 19226231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Initial observations on the efficacy of highly active antiretroviral therapy in the treatment of HIV-associated autoimmune thrombocytopenia.
    Aboulafia DM; Bundow D; Waide S; Bennet C; Kerr D
    Am J Med Sci; 2000 Aug; 320(2):117-23. PubMed ID: 10981487
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk factors for thrombocytopenia in HIV-infected persons in the era of potent antiretroviral therapy.
    Marks KM; Clarke RM; Bussel JB; Talal AH; Glesby MJ
    J Acquir Immune Defic Syndr; 2009 Dec; 52(5):595-9. PubMed ID: 19734800
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Surveillance for thrombocytopenia in persons infected with HIV: results from the multistate Adult and Adolescent Spectrum of Disease Project.
    Sullivan PS; Hanson DL; Chu SY; Jones JL; Ciesielski CA
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Apr; 14(4):374-9. PubMed ID: 9111481
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Measures of site resourcing predict virologic suppression, immunologic response and HIV disease progression following highly active antiretroviral therapy (HAART) in the TREAT Asia HIV Observational Database (TAHOD).
    Oyomopito R; Lee MP; Phanuphak P; Lim PL; Ditangco R; Zhou J; Sirisanthana T; Chen YM; Pujari S; Kumarasamy N; Sungkanuparph S; Lee CK; Kamarulzaman A; Oka S; Zhang FJ; Mean CV; Merati T; Tau G; Smith J; Li PC;
    HIV Med; 2010 Sep; 11(8):519-29. PubMed ID: 20345881
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of cytopenia and its associated factors among HIV infected adults on highly active antiretroviral therapy at Mehal Meda Hospital, North Shewa Zone, Ethiopia.
    Gebreweld A; Fiseha T; Girma N; Haileslasie H; Gebretsadik D
    PLoS One; 2020; 15(9):e0239215. PubMed ID: 32931523
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and Virologic Outcomes After Changes in First Antiretroviral Regimen at 7 Sites in the Caribbean, Central and South America Network.
    Wolff M; Shepherd BE; Cortés C; Rebeiro P; Cesar C; Wagner Cardoso S; Pape JW; Padgett D; Sierra-Madero J; Echevarria J; McGowan CC;
    J Acquir Immune Defic Syndr; 2016 Jan; 71(1):102-10. PubMed ID: 26761273
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Implementation of an antiretroviral access program for HIV-1-infected individuals in resource-limited settings: clinical results from 4 African countries.
    Sow PS; Otieno LF; Bissagnene E; Kityo C; Bennink R; Clevenbergh P; Wit FW; Waalberg E; Rinke de Wit TF; Lange JM;
    J Acquir Immune Defic Syndr; 2007 Mar; 44(3):262-7. PubMed ID: 17146376
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Magnitude and correlates of moderate to severe anemia among adult HIV patients receiving first line HAART in Northwestern Tanzania: a cross sectional clinic based study.
    Gunda DW; Kilonzo SB; Mpondo BC
    Pan Afr Med J; 2016; 23():26. PubMed ID: 27200131
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis.
    Gupta RK; Gregson J; Parkin N; Haile-Selassie H; Tanuri A; Andrade Forero L; Kaleebu P; Watera C; Aghokeng A; Mutenda N; Dzangare J; Hone S; Hang ZZ; Garcia J; Garcia Z; Marchorro P; Beteta E; Giron A; Hamers R; Inzaule S; Frenkel LM; Chung MH; de Oliveira T; Pillay D; Naidoo K; Kharsany A; Kugathasan R; Cutino T; Hunt G; Avila Rios S; Doherty M; Jordan MR; Bertagnolio S
    Lancet Infect Dis; 2018 Mar; 18(3):346-355. PubMed ID: 29198909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.